Enara Bio’s purpose is to shine a light on unconventional T cell targets to develop the next generation of cancer immunotherapies designed to treat broad patient populations. Enara’s proprietary EDAPT™ platform enables the discovery of Dark Antigens™, a novel source of shared, tumor-specific T cell targets derived from genomic dark matter. We are pioneering approaches to exploit these Dark Antigen targets with a range of immunotherapeutic modalities, including bispecific T-cell engagers, adoptive cell therapies and cancer vaccines. Based in Oxford, UK, Enara Bio is backed by RA Capital, Samsara Biocapital and SV Health Investors. For more information, please visit: www.enarabio.com Comments and DMs to this account are not monitored, for any further information please head to our website
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $17.5M
Founded date: 2016
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.11.2019 | Series A | $17.5M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 04.01.2024 | Boehringer Ingelheim licenses multiple Dark Antigens® from E... | Oxford, UK – January 04, 2024. Enara Bio today announces that Boehringer Ingelheim has exercised its... | svhealthin... |
| 28.09.2021 | Enara Bio announces the appointment of highly experienced bi... | Oxford, UK – 28th September 2021. Enara Bio, a biotechnology company advancing novel T-cell receptor... | svhealthin... |
| 12.01.2021 | Boehringer Ingelheim and Enara Bio Enter Strategic Collabora... | January 12, 2021 04:00 AM Eastern Standard Time INGELHEIM, Germany & OXFORD, England & LOND... | svhealthin... |
| 18.12.2020 | Immune Regulation makes Peter Greenleaf chairman and ... | Peter Greenleaf → In September, Immune Regulation raked in $53.4 million in a Series B fo... | endpts.com... |
| 09.12.2020 | Enara Bio relocates to The Oxford Science Park's newest faci... | OXFORD, England and LONDON, Dec. 9, 2020 /PRNewswire/ -- Enara Bio, a biotechnology company leveragi... | svhealthin... |
| 18.09.2020 | SV Health Investors welcomes six new Venture Partners to the... | Boston, MA & London, UK (September 18, 2020) – SV, a leading transatlantic healthcare venture ca... | svhealthin... |
| 03.06.2020 | Ervaxx rebrands as Enara Bio to reflect a broader emphasis o... | Oxford and London, UK – 3rd June 2020. Enara Bio™ (formerly Ervaxx™), a biotechnology company levera... | svhealthin... |